Shopping Cart 0
Cart Subtotal
AED 0

Aspergillosis - Pipeline Review, H2 2018

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Single User License
AED 7340

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Site License
AED 14680

Multiple Users within the Company/ Enterprise
Print Option: Yes
Copy Option: Yes
Deliverable Format : Excel, PDF Via Email

Corporate User License
AED 22020
  • Details
  • Table Of Content
  • Licence Rights
  • Section Purchase
  • Products and Companies

Details

Aspergillosis-Pipeline Review, H2 2018

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Aspergillosis-Pipeline Review, H2 2018, provides an overview of the Aspergillosis (Infectious Disease) pipeline landscape.

Aspergillosis is an infection or allergic response due to the Aspergillus fungus. Symptoms include cough, fever, headaches, general ill feeling (malaise), weight loss and chest pain. The predisposing factors include weakened immune system, low white blood cell level, asthma and long-term corticosteroid therapy. Treatment includes oral corticosteroids, antifungal and surgery.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Aspergillosis-Pipeline Review, H2 2018, provides comprehensive information on the therapeutics under development for Aspergillosis (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Aspergillosis (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Aspergillosis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, Preclinical and Unknown stages are 1, 2, 2, 5, 16 and 1 respectively. Similarly, the Universities portfolio in Phase II, Preclinical and Discovery stages comprises 1, 5 and 3 molecules, respectively.

Aspergillosis (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Aspergillosis (Infectious Disease).

- The pipeline guide reviews pipeline therapeutics for Aspergillosis (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.

- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

- The pipeline guide reviews key companies involved in Aspergillosis (Infectious Disease) therapeutics and enlists all their major and minor projects.

- The pipeline guide evaluates Aspergillosis (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

- The pipeline guide reviews latest news related to pipeline therapeutics for Aspergillosis (Infectious Disease)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

- Find and recognize significant and varied types of therapeutics under development for Aspergillosis (Infectious Disease).

- Classify potential new clients or partners in the target demographic.

- Develop tactical initiatives by understanding the focus areas of leading companies.

- Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.

- Formulate corrective measures for pipeline projects by understanding Aspergillosis (Infectious Disease) pipeline depth and focus of Indication therapeutics.

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

READ MORE

Table Of Content

Scope

Table of Contents

Table of Contents 2

Introduction 5

Aspergillosis-Overview 6

Aspergillosis-Therapeutics Development 7

Aspergillosis-Therapeutics Assessment 15

Aspergillosis-Companies Involved in Therapeutics Development 23

Aspergillosis-Drug Profiles 32

Aspergillosis-Dormant Projects 123

Aspergillosis-Discontinued Products 125

Aspergillosis-Product Development Milestones 126

Appendix 135


List Of Figure

List of Figures

Number of Products under Development for Aspergillosis, H2 2018

Number of Products under Development by Companies, H2 2018

Number of Products under Development by Universities/Institutes, H2 2018

Number of Products by Targets, H2 2018

Number of Products by Stage and Targets, H2 2018

Number of Products by Mechanism of Actions, H2 2018

Number of Products by Stage and Mechanism of Actions, H2 2018

Number of Products by Routes of Administration, H2 2018

Number of Products by Stage and Routes of Administration, H2 2018

Number of Products by Molecule Types, H2 2018

Number of Products by Stage and Molecule Types, H2 2018


List Of Table

List of Tables

Number of Products under Development for Aspergillosis, H2 2018

Number of Products under Development by Companies, H2 2018

Number of Products under Development by Universities/Institutes, H2 2018

Products under Development by Companies, H2 2018

Products under Development by Universities/Institutes, H2 2018

Number of Products by Stage and Target, H2 2018

Number of Products by Stage and Mechanism of Action, H2 2018

Number of Products by Stage and Route of Administration, H2 2018

Number of Products by Stage and Molecule Type, H2 2018

Aspergillosis-Pipeline by Amplyx Pharmaceuticals Inc, H2 2018

Aspergillosis-Pipeline by Astellas Pharma Inc, H2 2018

Aspergillosis-Pipeline by Basilea Pharmaceutica Ltd, H2 2018

Aspergillosis-Pipeline by Biosergen AS, H2 2018

Aspergillosis-Pipeline by Cerenis Therapeutics Holding SA, H2 2018

Aspergillosis-Pipeline by Cidara Therapeutics Inc, H2 2018

Aspergillosis-Pipeline by F2G Ltd, H2 2018

Aspergillosis-Pipeline by iCo Therapeutics Inc, H2 2018

Aspergillosis-Pipeline by Matinas BioPharma Holdings Inc, H2 2018

Aspergillosis-Pipeline by Mayne Pharma Group Ltd, H2 2018

Aspergillosis-Pipeline by Merck & Co Inc, H2 2018

Aspergillosis-Pipeline by Nanomerics Ltd, H2 2018

Aspergillosis-Pipeline by Novabiotics Ltd, H2 2018

Aspergillosis-Pipeline by Pulmatrix Inc, H2 2018

Aspergillosis-Pipeline by Pulmocide Ltd, H2 2018

Aspergillosis-Pipeline by Scynexis Inc, H2 2018

Aspergillosis-Pipeline by Sealife PHARMA GMBH, H2 2018

Aspergillosis-Pipeline by Viamet Pharmaceuticals Inc, H2 2018

Aspergillosis-Pipeline by Vical Inc, H2 2018

Aspergillosis-Pipeline by Visterra Inc, H2 2018

Aspergillosis-Dormant Projects, H2 2018

Aspergillosis-Discontinued Products, H2 2018

Licence Rights

Single User License:
Report can be used by individual purchaser only

Site License: 
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:  
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Section Purchase

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

Products and Companies

Products

Aspergillosis Therapeutic Products under Development, Key Players in Aspergillosis Therapeutics, Aspergillosis Pipeline Overview, Aspergillosis Pipeline, Aspergillosis Pipeline Assessment


Companies

Amplyx Pharmaceuticals Inc

Astellas Pharma Inc

Basilea Pharmaceutica Ltd

Biosergen AS

Cerenis Therapeutics Holding SA

Cidara Therapeutics Inc

F2G Ltd

iCo Therapeutics Inc

Matinas BioPharma Holdings Inc

Mayne Pharma Group Ltd

Merck & Co Inc

Nanomerics Ltd

Novabiotics Ltd

Pulmatrix Inc

Pulmocide Ltd

Scynexis Inc

Sealife PHARMA GMBH

Viamet Pharmaceuticals Inc

Vical Inc

Visterra Inc

Aspergillosis-Pipeline Review, H2 2018

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Aspergillosis-Pipeline Review, H2 2018, provides an overview of the Aspergillosis (Infectious Disease) pipeline landscape.

Aspergillosis is an infection or allergic response due to the Aspergillus fungus. Symptoms include cough, fever, headaches, general ill feeling (malaise), weight loss and chest pain. The predisposing factors include weakened immune system, low white blood cell level, asthma and long-term corticosteroid therapy. Treatment includes oral corticosteroids, antifungal and surgery.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Aspergillosis-Pipeline Review, H2 2018, provides comprehensive information on the therapeutics under development for Aspergillosis (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Aspergillosis (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Aspergillosis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, Preclinical and Unknown stages are 1, 2, 2, 5, 16 and 1 respectively. Similarly, the Universities portfolio in Phase II, Preclinical and Discovery stages comprises 1, 5 and 3 molecules, respectively.

Aspergillosis (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Aspergillosis (Infectious Disease).

- The pipeline guide reviews pipeline therapeutics for Aspergillosis (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.

- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

- The pipeline guide reviews key companies involved in Aspergillosis (Infectious Disease) therapeutics and enlists all their major and minor projects.

- The pipeline guide evaluates Aspergillosis (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

- The pipeline guide reviews latest news related to pipeline therapeutics for Aspergillosis (Infectious Disease)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

- Find and recognize significant and varied types of therapeutics under development for Aspergillosis (Infectious Disease).

- Classify potential new clients or partners in the target demographic.

- Develop tactical initiatives by understanding the focus areas of leading companies.

- Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.

- Formulate corrective measures for pipeline projects by understanding Aspergillosis (Infectious Disease) pipeline depth and focus of Indication therapeutics.

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

READ MORE

Scope

Table of Contents

Table of Contents 2

Introduction 5

Aspergillosis-Overview 6

Aspergillosis-Therapeutics Development 7

Aspergillosis-Therapeutics Assessment 15

Aspergillosis-Companies Involved in Therapeutics Development 23

Aspergillosis-Drug Profiles 32

Aspergillosis-Dormant Projects 123

Aspergillosis-Discontinued Products 125

Aspergillosis-Product Development Milestones 126

Appendix 135


List Of Figure

List of Figures

Number of Products under Development for Aspergillosis, H2 2018

Number of Products under Development by Companies, H2 2018

Number of Products under Development by Universities/Institutes, H2 2018

Number of Products by Targets, H2 2018

Number of Products by Stage and Targets, H2 2018

Number of Products by Mechanism of Actions, H2 2018

Number of Products by Stage and Mechanism of Actions, H2 2018

Number of Products by Routes of Administration, H2 2018

Number of Products by Stage and Routes of Administration, H2 2018

Number of Products by Molecule Types, H2 2018

Number of Products by Stage and Molecule Types, H2 2018


List Of Table

List of Tables

Number of Products under Development for Aspergillosis, H2 2018

Number of Products under Development by Companies, H2 2018

Number of Products under Development by Universities/Institutes, H2 2018

Products under Development by Companies, H2 2018

Products under Development by Universities/Institutes, H2 2018

Number of Products by Stage and Target, H2 2018

Number of Products by Stage and Mechanism of Action, H2 2018

Number of Products by Stage and Route of Administration, H2 2018

Number of Products by Stage and Molecule Type, H2 2018

Aspergillosis-Pipeline by Amplyx Pharmaceuticals Inc, H2 2018

Aspergillosis-Pipeline by Astellas Pharma Inc, H2 2018

Aspergillosis-Pipeline by Basilea Pharmaceutica Ltd, H2 2018

Aspergillosis-Pipeline by Biosergen AS, H2 2018

Aspergillosis-Pipeline by Cerenis Therapeutics Holding SA, H2 2018

Aspergillosis-Pipeline by Cidara Therapeutics Inc, H2 2018

Aspergillosis-Pipeline by F2G Ltd, H2 2018

Aspergillosis-Pipeline by iCo Therapeutics Inc, H2 2018

Aspergillosis-Pipeline by Matinas BioPharma Holdings Inc, H2 2018

Aspergillosis-Pipeline by Mayne Pharma Group Ltd, H2 2018

Aspergillosis-Pipeline by Merck & Co Inc, H2 2018

Aspergillosis-Pipeline by Nanomerics Ltd, H2 2018

Aspergillosis-Pipeline by Novabiotics Ltd, H2 2018

Aspergillosis-Pipeline by Pulmatrix Inc, H2 2018

Aspergillosis-Pipeline by Pulmocide Ltd, H2 2018

Aspergillosis-Pipeline by Scynexis Inc, H2 2018

Aspergillosis-Pipeline by Sealife PHARMA GMBH, H2 2018

Aspergillosis-Pipeline by Viamet Pharmaceuticals Inc, H2 2018

Aspergillosis-Pipeline by Vical Inc, H2 2018

Aspergillosis-Pipeline by Visterra Inc, H2 2018

Aspergillosis-Dormant Projects, H2 2018

Aspergillosis-Discontinued Products, H2 2018

Single User License:
Report can be used by individual purchaser only

Site License: 
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:  
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

Products

Aspergillosis Therapeutic Products under Development, Key Players in Aspergillosis Therapeutics, Aspergillosis Pipeline Overview, Aspergillosis Pipeline, Aspergillosis Pipeline Assessment


Companies

Amplyx Pharmaceuticals Inc

Astellas Pharma Inc

Basilea Pharmaceutica Ltd

Biosergen AS

Cerenis Therapeutics Holding SA

Cidara Therapeutics Inc

F2G Ltd

iCo Therapeutics Inc

Matinas BioPharma Holdings Inc

Mayne Pharma Group Ltd

Merck & Co Inc

Nanomerics Ltd

Novabiotics Ltd

Pulmatrix Inc

Pulmocide Ltd

Scynexis Inc

Sealife PHARMA GMBH

Viamet Pharmaceuticals Inc

Vical Inc

Visterra Inc